eISSN: 1644-4124
ISSN: 1426-3912
Central European Journal of Immunology
Current issue Archive Manuscripts accepted About the journal Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank

2/2019
vol. 44
 
Share:
Share:
more
 
 
abstract:
Experimental immunology

Effect of selected non-steroidal anti-inflammatory drugs on activation-induced CD25 expression on murine CD4+ and CD8+ T cells: an in vitro study

Izabela Gregorczyk
,
Tomasz Maślanka

(Centr Eur J Immunol 2019; 44 (2): 109-118)
Online publish date: 2019/07/30
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
The main aim of this study has been to determine the effect of selected non-steroidal anti-inflammatory drugs (NSAIDs) – depending on their selectivity to cyclooxygenase (COX) 1 and 2 – on the activation-induced CD25 expression on CD4+ and CD8+ T cells. Lymphocytes obtained from lymph nodes of mice were treated with acetylsalicylic acid (ASA; a preferential COX-1 inhibitor), ketoprofen (KET; a non-selective COX inhibitor) and robenacoxib (ROB; a selective COX-2 inhibitor) in concentrations reflecting their plasma levels achieved in vivo at therapeutic doses and in ten-fold lower concentrations. The cells were activated with concanavalin A. In contrast to KET and ROB, ASA had no effect on the activation-induced CD25 expression on CD4+ and CD8+ T cells, nor did it affect the counts of CD4+ and CD8+ activated effector (aTeff) and resting (Trest) T cells. Both KET and ROB caused a depletion of CD8+ aTeff cells, and additionally KET induced a loss of CD8+ Trest cells. Moreover, ROB, but not the other drugs, reduced the activation-induced CD25 expression on CD4+ T cells. This suggests that non-selective COX inhibitors and selective COX-2 inhibitors may weaken the effector T cell response by producing a negative effect on the count of aTeff cells. Furthermore, the results seem to imply that ASA and KET have certain potential to induce Foxp3 expression in CD25+CD8+ and CD25+CD4+ T cells, respectively. However, all the observed changes were very weakly manifested and therefore it is not certain whether they have clinical importance, despite the statistical significance determined.
keywords:

NSAIDs, COX, T cell activation, CD4, CD8, CD25, Foxp3

FEATURED PRODUCTS
Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe